|

Multi-Site Trial of Navigation vs Treatment as Usual to Improve Initiation of Timely Adjuvant Therapy

RECRUITINGN/ASponsored by Medical University of South Carolina
Actively Recruiting
PhaseN/A
SponsorMedical University of South Carolina
Started2023-10-30
Est. completion2028-03-30
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations4 sites

Summary

The goal of this clinical trial is to compare the effectiveness of a navigation-based multilevel intervention (ENDURE) with treatment as usual (TAU) to improve the initiation of guideline-adherent postoperative radiation therapy among patients with head and neck cancer. The main questions the trial aims to answer are: 1. Does ENDURE improve initiation of timely PORT relative to treatment as usual? 2. What are the mechanisms through which ENDURE improves timeliness to treatment? 3. What are the barriers and facilitators to the implementation of ENDURE into routine clinical care?

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

1. Age \>/= 18 years
2. Squamous cell carcinoma (SCC) (or histologic variant) of the oral cavity, oropharynx, hypopharynx, larynx, unknown primary, paranasal sinuses, or nasal cavity
3. American Joint Committee on Cancer (AJCC) 8th edition clinical T3-4 or \>N1 SCC of the oral cavity, oropharynx, hypopharynx, larynx, paranasal sinuses, nasal cavity, or unknown primary.
4. No history of radiation therapy for treatment of HNSCC in the definitive or adjuvant settings that would, at the discretion of the enrolling clinician, affect the patient's need for adjuvant RT.
5. Plan for curative intent surgery at one of the participating centers
6. Plan for PORT (regardless of whether it is at the surgical center) with or without concurrent chemotherapy following curative intent surgery based on the expectation of at least one of the following adverse features on final pathologic evaluation: pT3 or pT4 primary, N1 or greater nodal disease, perineural invasion (PNI), or lymphovascular invasion (LVI).

Exclusion Criteria:

1. Inability to speak or read English or Spanish.
2. Severe mental illness that would prevent trial participation.
3. HPV-positive OPC or unknown primary SCC staged as cT1-2N1 with a single ipsilateral LN \< 3 cm
4. Synchronous untreated malignancy expected to impact life expectancy

Conditions6

CancerHead and Neck CancerHead and Neck Squamous Cell CarcinomaLarynx CancerOral Cavity CancerOropharynx Cancer

Locations4 sites

Missouri

1 site
Washington University in St. Louis
St Louis, Missouri, 63110
Ryan Jackson, MD314 362 8641jackson.ryan@wustl.edu

North Carolina

1 site
Duke University Medical Center
Durham, North Carolina, 27710
Russel R Kahmke, MD, MMCi

South Carolina

1 site
Medical University of South Carolina
Charleston, South Carolina, 29425
Evan Graboyes, M.D., MPH, FACS(843) 792-0719graboyes@musc.edu

Texas

1 site
Baylor College of Medicine
Houston, Texas, 77030
Vlad C Sandulache, MD, PhD

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.